Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1530

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Sacituzumab tirumotecan
DRUG: Capecitabine

Sponsor

Merck Sharp & Dohme LLC